LMNA and dilated cardiomyopathy: Doxorubicin- and daunorubicin-treated clusters were identified by substantial downregulation of ANKRD1 (associated with dilated cardiomyopathy), LMNA (Lamin A/C; known mutations result in cardiomyopathy), as well as NKX2-5,and GATA4 (two transcription factors essential for cardiac development and survival).